We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
-34.99%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$100M
AUM Growth
-$86.8M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
10
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$31.3M 31.24%
498,558
PASG icon
2
Passage Bio
PASG
$14.7M
$15.4M 15.35%
247,988
GRTS
3
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$14.7M 14.65%
3,561,150
CRNX icon
4
Crinetics Pharmaceuticals
CRNX
$8.88B
$9.01M 8.99%
410,360
AKRO
5
DELISTED
Akero Therapeutics
AKRO
$8.77M 8.75%
617,727
UTRS
6
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$7.53M 7.52%
83,685
ADVM
7
DELISTED
Adverum Biotechnologies
ADVM
$6.64M 6.63%
506,823
ALGS icon
8
Aligos Therapeutics
ALGS
$26.3M
$4.99M 4.98%
92,815
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
$1.69M 1.69%
543,753
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
$206K 0.21%
101,855

Similar funds

Versant Venture Management's Q1 2022 Portfolio in Review

As of Q1 2022, Versant Venture Management held 10 positions worth $100M, down 46% from $187M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2022: portfolio turnover was 0%. Versant Venture Management opened no new positions and made no exits, leaving the 10-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Versant Venture Management's ten largest holdings make up 100% of its $100M portfolio in Q1 2022.
  • Versant Venture Management opened 0 new positions and closed 0 in Q1 2022.
  • Versant Venture Management's portfolio value fell 46% quarter-over-quarter to $100M.

Based on Versant Venture Management's 13F filing for Q1 2022, filed 10 May 2022.